Adjuvant RT improves breast cancer–specific survival in estrogen receptor-negative/ERBB2-negative breast cancerPoor differentiation, estrogen receptor-negative/ERBB2-negative breast cancer favors RT; predicts poorer outcomes. Here, ERBB2 is linked to breast carcinoma.